Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
“we're hopeful that we'll have data back from that in the second half of 'twenty seven”
→ Read the source episode
Our resolution criterion
disputableAvalon Pharma publicly announces Phase 2b clinical trial data for APL1 program
More from The Long Run with Luke Timmerman
Matai Mammen predicts Parabolas will eventually conduct a basket trial using a genetic signature to enroll multiple tumor types responsive to zolucatotide
Matai Mammen predicts Parabolas will initiate Phase 3 trials for zolucatotide in desmoid tumors in H1 2027
Maize Therapeutics will determine within the next year whether its APOL1 and SLC6A19 programs pass phase two clinical trial scrutiny.
Maize Therapeutics will have initiated a pivotal study on APOL1 and advanced other programs through mid-stage development by August 2027.
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.